Calamos Advisors LLC Sells 122,909 Shares of Abbott Laboratories $ABT

Calamos Advisors LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 24.5% during the first quarter, Holdings Channel reports. The fund owned 378,774 shares of the healthcare product maker’s stock after selling 122,909 shares during the quarter. Calamos Advisors LLC’s holdings in Abbott Laboratories were worth $38,889,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. AMG National Trust Bank raised its stake in shares of Abbott Laboratories by 37.1% during the first quarter. AMG National Trust Bank now owns 45,379 shares of the healthcare product maker’s stock valued at $4,659,000 after acquiring an additional 12,288 shares during the last quarter. Mattern Capital Management LLC grew its holdings in Abbott Laboratories by 48.8% in the first quarter. Mattern Capital Management LLC now owns 105,888 shares of the healthcare product maker’s stock worth $10,872,000 after purchasing an additional 34,719 shares during the period. Legacy Capital Group California Inc. lifted its holdings in shares of Abbott Laboratories by 32.0% in the 1st quarter. Legacy Capital Group California Inc. now owns 7,883 shares of the healthcare product maker’s stock worth $809,000 after purchasing an additional 1,909 shares in the last quarter. HBW Advisory Services LLC boosted its stake in Abbott Laboratories by 9.1% during the 1st quarter. HBW Advisory Services LLC now owns 2,494 shares of the healthcare product maker’s stock valued at $256,000 after purchasing an additional 209 shares during the last quarter. Finally, TFR Capital LLC. raised its holdings in shares of Abbott Laboratories by 16.7% in the first quarter. TFR Capital LLC. now owns 4,680 shares of the healthcare product maker’s stock valued at $480,000 after purchasing an additional 671 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 2.0%

ABT opened at $92.01 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm’s fifty day moving average is $89.23 and its 200 day moving average is $102.86. The stock has a market cap of $160.27 billion, a price-to-earnings ratio of 25.77, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ABT shares. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Sanford C. Bernstein dropped their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Mizuho reduced their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.42.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.